Outcomes with allogeneic hematopoietic stem cell transplantation in TP53-mutated acute myeloid leukemia: a systematic review and meta-analysis

References

• Yoshizato TY, Atsuta Y, Shiozawa Y, et al. Genetic abnormalities in myelodysplasia and secondary acute myeloid leukemia: impact on outcome of stem cell transplantation. Blood. 2017;129(17):2347–2358.
   PubMed Web of Science ®Google Scholar
• Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature. 2000;408(6810):307–310.
   PubMed Web of Science ®Google Scholar
• Boettcher S, Miller PG, Sharma R, et al. A dominant-negative effect drives selection of TP53 missense mutations in myeloid malignancies. Science. 2019;365(6453):599–604.
   PubMed Web of Science ®Google Scholar
• Brown CJ, Lain S, Verma CS, et al. Awakening guardian angels: drugging the p53 pathway. Nat Rev Cancer. 2009;9(12):862–873.
   PubMed Web of Science ®Google Scholar
• Welch JS, Petti AA, Miller CA, et al. TP53 and decitabine in acute myeloid leukemia and myelodysplastic syndromes. N Engl J Med. 2016;375(21):2023–2036.
   PubMed Web of Science ®Google Scholar
• Schoch C, Kern W, Kohlmann A, et al. Acute myeloid leukemia with a complex aberrant karyotype is a distinct biological entity characterized by genomic imbalances and a specific gene expression profile. Genes Chromosomes Cancer. 2005;43(3):227–238.
   PubMed Web of Science ®Google Scholar
• Olivier M, Hollstein M, Hainaut P. TP53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harb Perspect Biol. 2010;2(1):a001008.
   PubMed Web of Science ®Google Scholar
• Kim K, Maiti A, Loghavi S, et al. Outcomes of TP53-mutant acute myeloid leukemia with decitabine and venetoclax. Cancer. 2021;127(20):3772–3781.
   PubMed Web of Science ®Google Scholar
• Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339:b2700.
   PubMed Web of Science ®Google Scholar
• Schwarzer G. Meta: an R package for meta-analysis. R News. 2007;7(3):40–45.
   Google Scholar
• DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177–188.
   PubMedGoogle Scholar
• Middeke JM, Herold S, Rücker-Braun E, et al. TP53 mutation in patients with high-risk acute myeloid leukaemia treated with allogeneic haematopoietic stem cell transplantation. Br J Haematol. 2016;172(6):914–922.
   PubMed Web of Science ®Google Scholar
• Luskin MR, Carroll M, Lieberman D, et al. Clinical utility of next-generation sequencing for oncogenic mutations in patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2016;22(11):1961–1967.
   PubMed Web of Science ®Google Scholar
• Christopher J, Gibson M, Vincent TH III, et al. Genetic ontogeny defines distinct prognostic subgroups in AML patients age 60 and older following hematopoietic stem cell transplantation. Blood. 2017;130(Suppl. 1):3310.
   Google Scholar
• Grimm J, Jentzsch M, Bill M, et al. Prognostic impact of the ELN2017 risk classification in patients with AML receiving allogeneic transplantation. Blood Adv. 2020;4(16):3864–3874.
   PubMed Web of Science ®Google Scholar
• Yuho Najima M, Daichi Sadato M, Yuka Harada MP, et al. Presence of TP53 mutation and monosomal karyotype predict the outcome of patients with acute myeloid leukemia in non-remission at allogeneic stem cell transplantation. Blood. 2018;132(Suppl. 1):2168–2168.
   Google Scholar
• Short NJ, Montalban-Bravo G, Hwang H, et al. Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia. Blood Adv. 2020;4(22):5681–5689.
   PubMed Web of Science ®Google Scholar
• Justin Loke ML, Craddock C, Cornelissen J, et al. Disease risk in tp53 mutant acute myeloid leukaemia following an allogeneic stem cell transplant is dependent on the presence of co-existing cytogenetic features: a report from the ALWP of the EBMT. EHA. 2021;324640;S232.
   Google Scholar
• Badar T, Atallah E, Shallis RM, et al. Outcomes of TP53-mutated AML with evolving frontline therapies: impact of allogeneic stem cell transplantation on survival. Am J Hematol. 2022;97(7):E232–E235.
   PubMed Web of Science ®Google Scholar
• Yue X, Zhao Y, Xu Y, et al. Mutant p53 in cancer: accumulation, gain-of-function, and therapy. J Mol Biol. 2017;429(11):1595–1606.
   PubMed Web of Science ®Google Scholar
• Onyee Chan M, Hunter A, Talati C, et al. Impact of TP53 gene mutation clearance and conditioning intensity on outcome in MDS or AML patients prior to allogeneic stem cell transplantation. Blood. 2019;134(Suppl. 1):149.
   Google Scholar
• Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an International Expert Panel. Blood. 2017;129(4):424–447.
   PubMed Web of Science ®Google Scholar
• Murdock HM, Kim HT, Hambley BC, et al. Genetic alterations at diagnosis predict outcome of AML patients age 60 or older undergoing allogeneic transplantation in first remission. Blood. 2019;134(Suppl. 1):48.
   Google Scholar
• Britt A, Mohyuddin GR, McClune B, et al. Acute myeloid leukemia or myelodysplastic syndrome with chromosome 17 abnormalities and long-term outcomes with or without hematopoietic stem cell transplantation. Leuk Res. 2020;95:106402.
   PubMed Web of Science ®Google Scholar
• Poiré X, Labopin M, Maertens J, et al. Allogeneic stem cell transplantation in adult patients with acute myeloid leukaemia and 17p abnormalities in first complete remission: a study from the acute leukemia working party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT). J Hematol Oncol. 2017;10(1):20.
   PubMed Web of Science ®Google Scholar
• Mori J, Yanada M, Uchida N, et al. Outcomes of allogeneic hematopoietic cell transplantation in acute myeloid leukemia patients with abnormalities of the short arm of chromosome 17. Biol Blood Marrow Transplant. 2017;23(8):1398–1404.
   PubMed Web of Science ®Google Scholar
• Döhner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med. 2015;373(12):1136–1152.
   PubMed Web of Science ®Google Scholar
• Mishra A, Tamari R, DeZern AE, et al. Phase II trial of eprenetapopt (APR-246) in combination with azacitidine (AZA) as maintenance therapy for TP53 mutated AML or MDS following allogeneic stem cell transplantation (SCT). Blood. 2021;138(Suppl. 1):409.
   Google Scholar
• Byrne MT, Kurian TJ, Patel DA, et al. Non-relapse mortality in TP53-mutated MDS/AML –a multi-center collaborative study. Blood. 2021;138(Suppl. 1):2922.
   Google Scholar